Quantcast
Channel: DailyFinance.com
Viewing all 9760 articles
Browse latest View live

Small Businesses Have Just 12 Days to Suit Up for the Opportunity of a Lifetime

$
0
0

Filed under:

Small Businesses Have Just 12 Days to Suit Up for the Opportunity of a Lifetime

--(BUSINESS WIRE)-- Intuit Inc. (NAS: INTU) :

WHO:

  • Small business owners who want to share their stories with the world and have the chance to win $25 million in rewards.
  • Intuit Inc. (NAS: INTU) , a company whose mission is to improve its customers' financial lives.

WHAT:

  • Intuit Small Business Big Game, by Intuit QuickBooks kicked off July 31 and has already awarded $25,000 in prizes to deserving small businesses across the country.
  • One lucky business owner will win an all-expenses paid trip to New York and a 30-second custom television advertisement that will air during football's biggest game on February 2, 2014.
  • In addition to the grand prize giveaway, small businesses are eligible for weekly sweepstakes that include advertising credits, signed football memorabilia and more.
  • By telling their company story in 600 characters or less, everyone who enters receives a free Intuit Playbook and an Intuit QuickBooks special product offer. They can also connect with and learn from other small business owners who have similar challenges and goals.
  • Small businesses have just 12 days to get in the game as the entry period ends on Sunday, September 22, 2013 at 11:59 p.m. PT.

WHY:

  • Small businesses mean big business to the U.S. economy, driving job growth and fueling the gross domestic product. Their importance cannot be understated, and Intuit launched a program that provides a platform for them to share their passion and celebrate their success.
  • Since the program started on July 31, Intuit has seen thousands of entries from small businesses across the country in every state. Businesses entering include brick and mortar shops like florists and clothing boutiques to construction companies and plumbers. With 12 days left to enter, Intuit wants the rest of the 29 million small businesses across the US to get off the sidelines and have the chance to win big.

WHERE:



Intuit Inc.
Elisabeth Gettelman, 650-944-2116
egettelman@intuit.com
or
Access Communications
Jen Garcia, 415-844-6244
jgarcia@accesspr.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Small Businesses Have Just 12 Days to Suit Up for the Opportunity of a Lifetime originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments


New Data Evaluating Asfotase Alfa in Infants and Young Children with Hypophosphatasia (HPP) Presente

$
0
0

Filed under:

New Data Evaluating Asfotase Alfa in Infants and Young Children with Hypophosphatasia (HPP) Presented at Paediatric Endocrinology Meeting

- Early and Continued Improvement in Skeletal Mineralization Observed with 93% Survival in Studied Patients -

- Patients Also Improved or Preserved Respiratory Function -


CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NAS: ALXN) today announced that researchers have presented data from an ongoing multinational Phase 2 study of asfotase alfa in infants and young children with hypophosphatasia (HPP), an inherited, ultra-rare metabolic disorder that in this patient population leads to progressive damage to multiple vital organs, destruction and deformity of bones, and death.The study met its primary endpoint: infants and young children with HPP treated with asfotase alfa had significant improvement in skeletal mineralization from baseline as assessed radiographically after 24 weeks of treatment (p=0.001). This response was observed as early as 12 weeks and improvement continued at 48 weeks. Ninety three percent of the patients survived the first 48 weeks of treatment with 80% of patients having improved respiratory status or requiring no respiratory support at the final analysis. The data were presented in a late-breaking presentation at the 9th Joint Meeting of Paediatric Endocrinology in Milan, Italy.1

"Hypophosphatasia is a genetic, very rare metabolic disease that can have devastating and life-threatening consequences. HPP is characterized by profound hypomineralization and a number of systemic effects, including respiratory, neurologic and renal complications. Infants who develop their first symptoms of HPP before 6 months of age have a very poor prognosis with an estimated 50% mortality rate," said lead investigator Dr. Cheryl R. Greenberg, of the University of Manitoba in Winnipeg, Canada. "This study showed that treatment with asfotase alfa improved bone mineralization in infants and young children with HPP, and improved or preserved respiratory function, which is often a cause of death in these patients."

"We are excited about these results as they are consistent with previously reported positive data now in a broader patient population of infants and children," said Martin Mackay, Ph.D. Executive Vice President, Global Head of R&D at Alexion. "This further supports the potential of asfotase alfa as the first treatment for HPP, and we look forward to completing our registration program so that we may begin serving patients with this severe and often life-threatening disease."

Alexion is developing asfotase alfa as a potential treatment for HPP. Asfotase alfa was used on an investigational basis in the reported study. The U.S. Food and Drug Administration (FDA) recently designated asfotase alfa a Breakthrough Therapy for the treatment of patients with HPP whose first signs or symptoms occurred prior to 18 years of age, including perinatal-, infantile-, and juvenile-onset forms of the disease.

About the Phase 2 Trial of Asfotase Alfa in HPP

Results were presented from an ongoing multinational, Phase 2, open-label study that enrolled 15 infants and children with HPP (age 5 years or younger) representing a range of HPP characteristics; of this number, 13 patients were included in the Week 24 primary analysis. The median patient age at baseline was 21.14 weeks (range: 0.1-304.0 weeks), and all patients had experienced symptoms of HPP prior to 6 months old.1

The primary efficacy endpoint of the study was change in skeletal manifestations of HPP over time. The analysis presented today measured this endpoint as changes in the severity of rickets (softening and weakening of bones, which is unrelated to nutrition in patients with HPP) from baseline to Week 24, as assessed by the Radiographic Global Impression of Change (RGI-C) scale, a 7-point scale in which a rating of -3 represents severe worsening and a rating of +3 indicates near or complete healing. Response to treatment was defined as change from baseline in RGI-C of two or more points. Secondary endpoints included changes in respiratory support status, overall survival, and safety and tolerability.

Interim results presented today showed that the 13 evaluable patients treated with asfotase alfa had a significant improvement from baseline to Week 24 in skeletal mineralization, with a mean (standard deviation) increase in RGI-C score of 1.74 (1.107) and a median increase of 2.00 (p=0.001). Response to asfotase alfa therapy was evident as early as 12 weeks, with improvement continuing to Week 48. Eight of 12 evaluable patients were characterized as responders (defined as an RGI-C score of +2 [substantial healing] or greater) at Week 24, and all 10 of the evaluable patients at Week 48 were responders. Three patients had RGI-C scores of +3, which indicate near complete healing, at both Weeks 24 and 48.1

Additionally, the majority of patients (12/15) treated with asfotase alfa improved or preserved respiratory function. Among the eight patients who required respiratory support during the trial, five had improved by their last assessment, and four patients no longer required any support. The overall survival rate, another secondary endpoint, at 48 weeks was 93%. One patient in the study withdrew consent after receiving two doses of asfotase alfa; this patient later died from disease-related complications; the patient's death was deemed unrelated to the study drug.1

Asfotase alfa was well-tolerated in the study with no deaths, serious adverse events or discontinuations of therapy deemed related to treatment. The most common adverse events were mild to moderate injection site reactions, reported in 10 of the 15 patients (66.7%). These reactions included redness, (46.7%), discoloration, (26.7%), and hardening of the skin (13.3%). The trial continues to enroll patients and patients continue on treatment.1

About Hypophosphatasia (HPP)

HPP is a chronic, life-threatening, genetic, and ultra-rare metabolic disease characterized by defective bone mineralization and impaired phosphate and calcium regulation that can lead to progressive damage to multiple vital organs including destruction and deformity of bones, profound muscle weakness, seizures, impaired renal function, and respiratory failure.3-6

HPP is caused by a genetic deficiency of an enzyme known as tissue non-specific alkaline phosphatase (TNSALP), which causes life-long abnormalities in metabolism of two minerals, calcium and phosphate, leading directly to the debilitating morbidities and premature mortality of the disease.3

The genetic deficiency in HPP can affect people of all ages.3 HPP is traditionally classified by the age of the patient at the onset of the disease. Patients with perinatal-onset HPP manifest their first signs of disease in utero or at birth. This form of the disease is usually lethal and often leads to death in utero. Those patients who survive birth often have severely compromised respiratory function.7

Patients with infantile-onset HPP develop their first signs or symptoms of HPP before 6 months of age. Individuals with this form of disease develop skeletal abnormalities and may present with failure to thrive and respiratory failure within the first 6 months of post-natal life. The prognosis of these patients is very poor with mortality estimated at 50%.3

Patients with juvenile-onset HPP exhibit their first signs or symptoms of HPP after 6 months of age and before 18 years of age. Individuals with this form of the disease are at risk for respiratory complications, painful fractures, and profound muscle weakness and can have delayed acquisition of age-appropriate motor skills due to hypo-mineralization and muscle weakness leading to need for walking assistance; some may never walk.3

About Asfotase Alfa

Asfotase alfa is an investigational, highly innovative, first-in-class targeted enzyme replacement therapy. Asfotase alfa is designed to address the underlying cause of HPP by normalizing the genetically defective metabolic process, and preventing or reversing the severe and potentially life-threatening complications of life-long dysregulated mineral metabolism.

According to the FDA, a Breakthrough Therapy designation is designed to expedite the development of a drug to treat a serious or life-threatening disease when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The Breakthrough Therapy designation is part of the FDA Safety and Innovation Act (FDASIA) of 2012.8

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition, and has developed and markets Soliris® (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in more than 40 countries for the treatment of PNH, and in the United States, Europe, Japan and other territories for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris and is pursuing development of four other innovative biotechnology product candidates which are being investigated across additional severe and ultra-rare disorders beyond PNH and aHUS. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at www.alexionpharma.com.

[ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential medical benefits of asfotase alfa for hypophosphatasia (HPP). Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including, for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of asfotase alfa for HPP, delays in arranging satisfactory manufacturing capabilities and establishing commercial infrastructure for asfotase alfa for HPP, the possibility that results of clinical trials are not predictive of safety and efficacy results of asfotase alfa in broader or different patient populations, the risk that third party payors (including governmental agencies) will not reimburse for the use of asfotase alfa (if approved) at acceptable rates or at all, the risk that estimates regarding the number of patients with asfotase alfa and observations regarding the natural history of patients with asfotase alfa are inaccurate, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended June 30, 2013. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

References

  1. Greenberg CR, Vockley J, Harmatz P, Vallée M, Bedrosian CL, Liese JG. Asfotase alfa improves skeletal mineralization and respiratory function in infants and young children with hypophosphatasia: results from up to 12 months' treatment. Presented at the 9th Joint Meeting of Paediatric Endocrinology, Milan, Italy, Sept. 22, 2013. Abstr. FC20-1488.
  2. Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366:904-13.
  3. Whyte MP. Hypophosphatasia. In: Glorieux FH, Jueppner H, Pettifor J, eds. Pediatric bone: biology and diseases. 3rd ed. San Diego, CA: Academic Press, 2012: 771-94.
  4. Seshia SS, Derbyshire G, Haworth JC, Hoogstraten J. Myopathy with Hypophosphatasia. Arch Dis Child. 1990; 65(1):130-1.
  5. Whyte MP. Hypophosphatasia: nature's window on alkaline phosphatase function in humans. In: Principles of Bone Biology, 3rd Ed. Part II, Chapter 73: Molecular Mechanisms of Metabolic Bone Disease, Academic Press, 2008: 1573-98.
  6. Silver MM, Vilos GA, Milne KJ. Pulmonary hypoplasia in neonatal hypophosphatasia. Pediatr Pathol. 1998; 8:483-93.
  7. Whyte MP. Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: Clinical and laboratory aspects. Crit Rev Clin Lab Sci. 1991; 23:175-195.
  8. Public Law 112-144. U.S. Government Printing Office, July 9, 2012. http://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf.



Alexion Pharmaceuticals, Inc.
Irving Adler, 203-271-8210
Exec. Director, Corporate Communications
or
Media:
Alexion Pharmaceuticals, Inc.
Kim Diamond, 203-439-9600
Senior Director, Corporate Communications
or
Investors:
Rx Communications
Rhonda Chiger, 917-322-2569

KEYWORDS:   United States  Europe  North America  Connecticut  Switzerland

INDUSTRY KEYWORDS:

The article New Data Evaluating Asfotase Alfa in Infants and Young Children with Hypophosphatasia (HPP) Presented at Paediatric Endocrinology Meeting originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Investing Chicken: When to Sell Gilead Sciences

$
0
0

Filed under:

This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines and plays a game of investing chicken with the world's biggest biotech. Market Checkup gives a full examination of the recent regulatory action around potential new generic threat to a big-time blockbuster drug and looks at a study questioning the benefits of robotic surgery.

In this video, health-care analysts David Williamson and Max Macaluso play the always popular game of investing chicken with Gilead Sciences. The rules of the game are simple: What would have to go wrong with Gilead before it became a bad investment? Watch and find out how competitive threats and product launches can alter a bullish investor's perception of a stock.

Want to retire rich?
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.


The article Investing Chicken: When to Sell Gilead Sciences originally appeared on Fool.com.

David Williamson owns shares of Merck. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D., owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Towers Watson to Sell Reinsurance Brokerage Wing for $250 Million

$
0
0

Filed under:

Towers Watson will no longer be active in the reinsurance brokering sphere. The company announced that it will sell that part of its business to U.K.-based insurer Jardine Lloyd Thompson Group for $250 million in cash.

A joint press release issued by the two companies stated that Jardine will merge Towers Watson's unit with its own reinsurance operations to form the provisionally named JLT Towers Re. Combined, the two components brought in $266 million in revenue over the one-year period ending June 30, while employing roughly 700 people in 35 locations across 17 countries.

Towers Watson's current head of reinsurance brokerage, Ross Howard, will become executive chairman of JLT Towers Re. Alastair Speare-Cole, the CEO of Jardin's reinsurance arm, will also be CEO of the merged unit.


The deal is subject to approval from the relevant regulatory bodies. It is expected to close by the end of this calendar year.

Towers Watson shares closed up by nearly 3% to $102.99 on the day the deal was announced.

The article Towers Watson to Sell Reinsurance Brokerage Wing for $250 Million originally appeared on Fool.com.

Fool contributor Eric Volkman has no position in Towers Watson. Nor does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Whiting Petroleum Closes Williston Basin Acquisition

$
0
0

Filed under:

Whiting Petroleum's latest acquisition is now one for the history books. The company announced that it has closed a $260 million deal, first made public in August, to acquire 17,282 net acres along with production assets in the Williston Basin. Whiting had secured the properties from a private party that it did not name.

The land is located in Williams and McKenzie counties in North Dakota, and in Montana's Roosevelt and Richland counties. Oil and gas production from the company's new properties was estimated to average 2,420 barrels of oil equivalent per day this past August. Whiting Petroleum believes proven reserves there amounted to 17.1 million BOE as of Aug. 1.

The article Whiting Petroleum Closes Williston Basin Acquisition originally appeared on Fool.com.

Fool contributor Eric Volkman has no position in Whiting Petroleum. Nor does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

SurModics Board Chairman Set to Step Down

$
0
0

Filed under:

Diagnostic testing specialist SurModics announced on Friday that board Chairman Robert C. Buhrmaster, who joined the board of directors in 2008, will retire after the company's annual shareholder meeting, scheduled for February. He will be replaced by current board member Scott R. Ward, who will have his position filled in due course.

In thanking Buhrmaster for his service to the company and welcoming Ward into his new role, SurModics President and CEO Gary Maharaj said, "As we pursue our business strategy to grow SurModics' core businesses and expand beyond the core, Scott's extensive medical device and business experience will be invaluable."

Ward has more than 30 years of experience in the health-care industry, including 15 years as a senior operating business leader, most recently at Medtronic, where he served as senior VP and president of its cardiovascular business. Ward has been a director of SurModics since 2010 and serves as managing director at SightLine Partners and is the founder of Raymond Holdings. 


Burhmaster also offered up a vote of confidence for his successor, saying: "I am confident that this is the right time to pass the baton to a new board chair. I believe that Scott is the right person to guide SurModics to new levels of growth in its medical device and in vitro diagnostics businesses."

Headquartered in Eden Prairie, Minn., SurModics specializes in surface modification, drug delivery, and in vitro diagnostic technologies for the health-care industry.

The article SurModics Board Chairman Set to Step Down originally appeared on Fool.com.

Fool contributor Rich Duprey and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Sesa Goa Becomes Sesa Sterlite Following Merger

$
0
0

Filed under:

In a bit of musical chairs, Sesa Goa has changed its name to Sesa Sterlite following approval by the regulatory authorities in India, now that its acquisition of a number of companies creates a huge mining operation on the order of BHP Billiton and Rio Tinto.

In a process that began in February 2012, Vedanta Resources companies Sesa Goa, Sterlite Industries, Madras Aluminum, Sterlite Energy, and Vedanta Aluminum will join together under one roof, now called Sesa Sterlite. The only thing not transferred is Vedanta's Konkola copper mines in Zambia. 

The newly christened Sesa Sterlite announced on Friday that Goa's registrar of companies had approved the name chance on Sept. 18.


On Aug. 28, Sterlite shareholders got three shares of Sesa Goa for every five shares held while Madras Aluminum shareholders got seven shares for every 10 shares at two rupees each. A number of iron and metals mines have now become subsidiaries of Sesa Sterlite after the restructuring.

The new company had total assets worth $36 billion, cash and liquid investments of $7.7 billion, and profits of $1.9 billion as of the end of March. It also took on 87% of Vedanta's debt, which totals almost $16.6 billion at the end of the first calendar quarter. Sesa Sterlite now trades under the ticker symbol SSLT.

The article Sesa Goa Becomes Sesa Sterlite Following Merger originally appeared on Fool.com.

Fool contributor Rich Duprey and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Nielsen Clears Regulatory Hurdle for Arbitron Merger

$
0
0

Filed under:

Market research analyst Nielsen Holdings announced on Friday that it has reached an agreement with the FTC regarding its acquisition of rival researcher Arbitron . With that hurdle cleared, and pending completion of customary closing conditions, Nielsen expected the deal to close on Sept. 30.

Nielsen announced last Dec. 17 that it wanted to buy Arbitron for $48 a share, or $1.3 billion, cash, plus some minor debt financing. It expects the merger will add $0.26 to adjusted net income per share in the first full year of operations, and $0.32 of accretion to adjusted net income per share after the second year, reflecting an incremental $0.06 in the second year.

Saying the company was glad to have the regulatory approval process behind it and that the agreement reached with the agency is "highly acceptable," Nielsen CEO David Calhoun said, "We are looking forward to providing all of the benefits of the combined company to our new clients in the radio industry and their advertisers, driving incremental value for them as well as our shareholders."


The consent decree issued by the FTC says the agreement Arbitron had reached with ESPN and comScore last September to measure TV, radio, PC, mobile, and tablet engagement can remain in place, but if a third-party vendor comes along and agrees to a licensing deal, Nielsen would give them access to Arbitron PPM and related data, as well as software and technology currently being used in the ESPN project solely to measure the cross-platform data. This agreement will remain in place for eight years. 

Nielsen believes adding Arbitron to its stable will allow it to more broadly measure what consumers are watching and listening to around the world, as well as to delve deeper into the preferences of multicultural audiences in the United States.

The combined company will expand advertising effectiveness for radio clients and be better able to solve for unmeasured areas of media consumption, such as streaming audio and out-of-home. Because cross-platform measurement is still in its infancy, Nielsen will now have the opportunity to put its stamp on what the outcome will be.

The article Nielsen Clears Regulatory Hurdle for Arbitron Merger originally appeared on Fool.com.

Fool contributor Rich Duprey and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments


Will GM Be the First to Beat Tesla Motors?

$
0
0

Filed under:

Right now, Tesla's impressive Model S is the only serious all-electric luxury car. But there are more and more signs that legit competition for Tesla is on the horizon. Photo credit: Tesla Motors.

Tesla Motors has wowed the world with its first mass-produced model, the all-electric Model S luxury sedan. It's a superb product. But the Model S is expensive: Even the most basic versions cost more than $60,000. Tesla CEO Elon Musk says his company will have a more affordable model in a few years -- but will that model be playing catch-up from the start?


It's looking possible. From the start, sophisticated investors have viewed Tesla's prospects warily, worried about competition from the world's automotive giants. Tesla has brains, guts, and momentum, no doubt -- but the big automakers have resources that Tesla won't be able to match for years, if ever.

So far, that competition has yet to materialize, but there are more and more signs that it's coming. The latest: General Motors said this past week that it's working on an electric car that will have 200 miles of range -- and cost just $30,000, a price that will challenge (and might even undercut) the upcoming "affordable" Tesla.

Of course, it's one thing for any company to claim that it's "working on" a breakthrough product, and another thing entirely to deliver it. Tesla's track record to date inspires some confidence. How seriously should we take GM? In this video, Fool contributor John Rosevear takes a deeper look at what could be coming from GM -- and at the likelihood that the Rust Belt giant could really trump Silicon Valley's auto darling.

An oil-price spike will help more than electric-car sales
An increase in oil prices will only help Tesla's sales. But with a return to $100 oil looking more and more likely, how else can smart investors position themselves to benefit? To help investors get rich off of rising oil prices, our top analysts prepared a free report that reveals three more stocks that are bound to soar as oil prices climb higher. To discover the identities of these stocks instantly, access your free report by clicking here now.

The article Will GM Be the First to Beat Tesla Motors? originally appeared on Fool.com.

Fool contributor John Rosevear owns shares of Ford and General Motors. You can connect with him on Twitter at @jrosevear. The Motley Fool recommends Ford, General Motors, and Tesla Motors and owns shares of Ford and Tesla Motors. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

7 Steps to Beat the Market

$
0
0

Filed under:

In this segment from The Motley Fool's everything-financials show, Where the Money Is, financials analysts Matt Koppenheffer reviews his investment process and tells fellow analyst David Hanson and viewers why he's adding AIG to the real-money portfolio he manages on behalf of The Motley Fool.

Refine your process!
Have you missed out on the massive gains in bank stocks over the past few years? There's good news: It's not too late. Bargains of a lifetime are still available, but you need to know where to look. The Motley Fool's new report "Finding the Next Bank Stock Home Run" will show you how and where to find these deals. It's completely free -- click here to get started.


The article 7 Steps to Beat the Market originally appeared on Fool.com.

David Hanson owns shares of American International Group. Matt Koppenheffer owns shares of American International Group. The Motley Fool recommends American International Group, Coca-Cola, and Wells Fargo. The Motley Fool owns shares of American International Group and Wells Fargo and has the following options: long January 2014 $25 calls on American International Group. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

1 Bank Aggressively Lending to Businesses

$
0
0

Filed under:

Commercial and industrial loans for banks have often been a great source of revenue for banks. Often the loans are simpler and less complex products than those dreamed up in investment banks, and are made to small- and medium-sized companies that are generally the stalwarts of the American economic engine.

The Federal Reserve reported that total outstanding commercial and industrial loans in August stood at $1.57 trillion, nearly eclipsing the peak of $1.61 trillion seen in October 2008. This comes after outstanding loans fell 25% to $1.2 trillion in October 2010.

To see which regional bank that has been outpacing its peers in its growth of commercial loans on the balance sheet, click the slideshow below. Also, if you have you missed out on the massive gains in bank stocks over the past few years, there's good news: It's not too late. Bargains of a lifetime are still available, but you need to know where to look. The Motley Fool's new report "Finding the Next Bank Stock Home Run" will show you how and where to find these deals. It's completely free -- click here to get started.


1 Bank Aggressively Lending to Businesses from The Motley Fool.

The article 1 Bank Aggressively Lending to Businesses originally appeared on Fool.com.

Fool contributor Patrick Morris owns shares of U.S. Bancorp. The Motley Fool owns shares of Fifth Third Bancorp and PNC Financial Services. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

United Online Extends Spinoff Timetable of FTD

$
0
0

Filed under:

Internet-based consumer products and services provider United Online announced on Fridday that it's extending for one month its previously announced separation of its FTD subsidiary. The online retailer had previously said it was targeting Oct. 1 as the spinoff date for the floral delivery service, but it has now pushed the date back to Nov. 1.

Saying the company is still committed to the spinoff, United Online Chairman, President, and CEO Mark R. Goldston said: "We continue to believe that the tax-free spinoff of FTD will unlock value for the benefit of our stockholders and provide significant operational and strategic flexibility for both FTD and United Online, better position them to capitalize on their well-recognized brands, and enhance long-term stockholder value."

Under the terms of the separation previously announced, for every five shares of United Online stock that's held on the record date of the spinoff, the shareholder will received one share of FTD's common stock. The record date is still to be determined.


In addition, United Online expects to implement a 1-for-7 reverse stock split of shares of its own common stock immediately before the spinoff of FTD. It offers the example that for every 35 shares of United Online common stock owned, the shareholder would hold seven shares of FTD stock and five shares of United Online stock immediately after the spinoff and reverse stock split are completed.

While the spinoff is expected to be tax-free, a letter from the IRS still needs to be received acknowledging as much before the deal can be completed, along with the usual and customary requirements to which the spinoff is subject.

The article United Online Extends Spinoff Timetable of FTD originally appeared on Fool.com.

Fool contributor Rich Duprey has no position in any stocks mentioned. The Motley Fool owns shares of United Online. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

San Juan Basin Sets Monthly Distribution

$
0
0

Filed under:

San Juan Basin Royalty Trust announced on Friday its October monthly distribution of $0.094625 per unit, based principally upon production during July.

The board of directors said the dividend is payable on Oct. 15 to the holders of record at the close of business on Sept. 30. The trust reported that gas production for the properties from which the royalty was carved totaled approximately 2,949,189 million cubic feet, or 3,255,683 million BTUs.

Dividing revenues by production volume yielded an average gas price for July of $3.45 per Mcf ($3.12 per MMBtu) as compared with $3.72 per Mcf ($3.37 per MMBtu) for June. The distribution to the trust in any given month may include significant volume adjustments for sales in prior months that reflect pricing for those prior months.


The latest payment would equate to an approximately $1.14-per-unit annual dividend, yielding 6.9% based on the closing price of San Juan Realty Trust's stock on Sept. 20.

The article San Juan Basin Sets Monthly Distribution originally appeared on Fool.com.

Fool contributor Rich Duprey and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Buffalo Wild Wings Woos Diners, One Beer at a Time

$
0
0

Filed under: , , , ,

Buffalo Wild Wings beer
Tony Tribble, Invision/AP
By Tom Rotunno

Forget about Bloomin' Onions or boneless wings, for many consumers, the choice of where to dine often comes down to a different factor: which restaurant has the best booze.

"Alcoholic beverages can be a key driver of traffic, differentiation, and loyalty," said David Decker, president of Consumer Edge Insight. According to the firm, two factors that keep customers coming back are "selection" and "pricing."

Consumer Edge Insight recently surveyed restaurant customers to find out which casual-dining spots generated the most loyalty with their alcoholic beverages.

Taking the top spot for "selection" was Buffalo Wild Wings (BWLD), with 29 percent of those surveyed saying they were "most likely to visit it most often due to its good selection of alcoholic beverages."

Applebee's (DIN) took the second spot, with 24 percent, and Outback Steakhouse (BLMN) and T.G.I. Friday's tied for third place with 22 percent each.

Prices also keep customers coming back to Buffalo Wild Wings.

When asked which casual-dining brand they were "most likely to visit most often due to its good prices of alcoholic beverages," Buffalo Wild Wings came out on top with 30 percent. Chili's (EAT) was No. 2 at 23 percent, and Ruby Tuesday (RT) was third with 22 percent.

Buffalo Wild Wings has always made alcohol a part of its experience, even making it part of its tagline: "Wings.Beer.Sports."

The chain is the No. 1 account for more than 50 different beer brands and recently launched Game Changer, a new beer in a partnership with Redhook Brewery. Priced between cheaper domestic lagers and pricier craft beers, Game Changer became the fourth-most-popular draft beer at company-owned locations within two weeks of its release.

"Among casual-dining restaurants, Buffalo Wild Wings is seeing the greatest positive effect in terms of building customer loyalty with its alcohol offerings," Decker said. "There are many steps other restaurants can take to improve their alcoholic beverage programs to increase traffic, sales and customer loyalty."

Among the restaurants with room for improvement was Hooters, which 46 percent of those surveyed cited as the place they would visit more often if the chain offered a better selection of alcoholic beverages.

Lone Star Steakhouse had the highest number of customers saying they would visit more often if the chain offered better prices on alcoholic beverages.


More from CNBC:

%Gallery-187720%

 

Permalink | Email this | Linking Blogs | Comments

Enduro Sets Monthly Distribution

$
0
0

Filed under:

Statutory trust Enduro Royalty Trust announced on Friday its October monthly distribution of $0.127255 per unit; it has paid a monthly dividend since November 2011. 

The board of directors said the monthly distribution is payable on Oct. 15 to the holders of record at the close of business on Sept. 30. The trust was formed by Enduro Resource Partners for the purpose of receiving 80% of the net profits from the sale of oil and natural gas production from certain properties in Texas, Louisiana, and New Mexico.

Enduro noted that there was significant decrease in natural gas production because of approximately 258,000 Mcf that was paid by an operator during the previous calculation period for 23 months of production from a well in north Louisiana, resulting in $780,000 in additional natural gas revenues during the prior month's calculation period. Excluding the adjustment, realized natural gas prices for the prior month were $4.03 per Mcf.


The regular dividend payment would equate to approximately a $1.53-per-unit annual dividend, which would yield 10.1% based on the closing price of Enduro Royalty Trust's stock on Sept. 20.

The article Enduro Sets Monthly Distribution originally appeared on Fool.com.

Fool contributor Rich Duprey and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments


Will Obamacare Help or Hurt Medical-Device Stocks?

$
0
0

Filed under:

Medical-device makers have gotten hurt under Obamacare, with tax provisions hitting their bottom lines in an already tough economic environment. What will the future bring for the industry?

In the following video, Dan Caplinger, The Motley Fool's director of investment planning and author of the special free report "Everything You Need to Know About Obamacare," talks with Motley Fool health-care bureau chief Max Macaluso about the state of the medical-device industry and the impact that the Patient Protection and Affordable Care Act will have on it. Dan notes that diversified companies Medtronic and Stryker have largely avoided the negative impact of a 2.3% excise tax that Obamacare imposed on their revenue, posting gains of around 25% over the past year. But smaller players Intuitive Surgical and MAKO Surgical haven't fared as well, with losses of 10% to 25% since this time last year.

Max and Dan discuss a number of factors explaining the disparity, only some of which have to do with the Obamacare tax. Controversy about Intuitive Surgical's da Vinci robotic surgical systems have weighed on the stock and also caused some collateral damage to MAKO as well, but another big problem has come from hospitals and doctors that are less willing to make major capital expenditures on medical equipment. Dan suggests that broadening your exposure beyond specialists such as Medtronic and Stryker to look at more diversified health-care giant Johnson & Johnson might help you dampen any negative impact from the Obamacare tax.


Where are Obamacare's winners?
Medical-device makers aren't the only stocks affected by Obamacare. Find out which companies are most likely to see the biggest gains by reading our free report, in which Dan walks you through the opportunities and the companies that are positioned to exploit them. Get your copy right now; just click here to get started.

The article Will Obamacare Help or Hurt Medical-Device Stocks? originally appeared on Fool.com.

Neither Fool contributor Dan Caplinger nor Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool recommends Intuitive Surgical, Johnson & Johnson, and MAKO Surgical and owns shares of Intuitive Surgical, Johnson & Johnson, and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

European Commission Approves Vodafone KDH Acquisition

$
0
0

Filed under:

Vodafone will soon expand outside the wireless space in continental Europe with the purchase of a big asset in Germany. The European Commission, the executive body of the European Union, has approved the company's purchase of cable provider Kabel Deutschland Holding.

Vodafone launched a public takeover attempt for the German concern at the end of July, offering 84.50 euros ($114.25) per share in cash. The company also promised to follow through with the 2.50 euros ($3.38)-per-share dividend KDH pledged to its stockholders. All told, the telecom will spend an estimated 7.7 billion euros ($10.4 billion) to acquire its target.

In the press release announcing its decision, the EC said it found that "in markets where the parties' activities overlap, the increase in market share resulting from the proposed transaction is insignificant and will therefore not appreciably alter competition." 


According to an SEC document it filed on Sept. 17, Vodafone had secured more than 76% of KDH's outstanding shares. It has extended its deadline for existing stockholders to tender their shares to Sept. 30, more than two weeks past the original cutoff date of Sept. 11.

The article European Commission Approves Vodafone KDH Acquisition originally appeared on Fool.com.

Fool contributor Eric Volkman has no position in Vodafone. The Motley Fool recommends Vodafone. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Apollo Residential Mortgage Cuts Common Stock Dividend

$
0
0

Filed under:

In the latest of a series of dividend cuts in the REIT space, Apollo Residential Mortgage has reduced its common stock distribution. The company declared a disbursement of $0.40 per share for its Q3, to be handed out on Oct. 31 to holders of record as of Sept. 30. That amount is $0.30, or 43%, below each of the firm's three preceding payouts of $0.70 apiece, the most recent of which was dispensed at the end of July.

The REIT also declared a dividend on its series A preferred stock of $0.50 per share, with the same payment and record dates as those of the common shares.

The just-declared common stock dividend annualizes to $1.60 per share. That yields 10.3% at Apollo Residential Mortgage's most recent closing stock price of $15.60.

The article Apollo Residential Mortgage Cuts Common Stock Dividend originally appeared on Fool.com.

Fool contributor Eric Volkman has no position in Apollo Residential Mortgage. Nor does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

A Swing and a Miss With the iPad Mini Retina

$
0
0

Filed under:

With Apple's iPad mini with Retina display reported hitting physical and virtual store shelves, it makes sense to look at what this product could mean for the company. When the first iPad mini was introduced at a price of $329, many believed this was Apple beginning to realize that it had to lower prices to keep its tablet market share. However, with the latest mini priced at $399, the company seems to have reversed course and that may spell trouble for the iPad division.

Why small tablets?
It's well known that tablets are cannibalizing PC sales and that consumers are finding more and more reasons to own this type of device. Whether it's Apple showing a customer using FaceTime or Google featuring its Google Now service on an Android device, there are many reasons a tablet may be better than a traditional PC.

If you like reading, Amazon.com hopes that you'll consider its Kindle Fire lineup to get your digital page turning fix. Of course, Samsung isn't going to cede market share to anyone, and the company is pushing the smartphone and tablet combination with the Galaxy Note III and also offers the Galaxy Note 8 if you want a true tablet experience.


According to IDC research, in the first quarter of this year one in every two tablets shipped was below eight inches in screen size. In addition, IDC expects smaller tablets to continue to grow in 2013 and beyond.

What customers wanted, and what they got
Going into the iPad lineup refresh, most expected a thinner, lighter, and better full-sized iPad, and that's pretty much what they got with the iPad Air. Apple kept to its practice of staying at the same price point and at $499 the iPad Air is without question the best full-sized iPad.

However, when it comes to the mini, Apple's magic of delivering the same price with better specs got left by the wayside. While the mini does sport the Retina display, a better processor, and other improvements, the price jumped from $329 to $399. While it's true the first generation mini dropped to $299, this hardly makes the first generation device a bargain.

In fact, you could make the argument that the first generation mini is one of the worst combinations of price and display quality.

Device

Price

PPI

PPI per $1 of cost

iPad mini Retina

$399

326  

$1.22

iPad mini first gen.

$299

163  

$1.83

Google Nexus 7"

$229

323  

$0.71

Kindle Fire HDX 7"

$229

323  

$0.71

Galaxy Note 8"

$379

189  

$2.02

Given that display quality is a key factor in selecting a tablet, the iPad mini first generation seems to lag most of its peers. Given that this device also uses a dual-core processor whereas most of its competition uses quad-core processors or better, the difference is even starker.

The data above suggests that consumers shouldn't choose the iPad mini first generation, but what about the iPad mini with Retina display? The truth is, Apple is almost begging customers to just spend the extra $100 and get the iPad Air. The iPad mini with Retina display is priced higher than any of the devices we've mentioned by as much as 70%.

In addition, the weight and size difference between the full-sized and iPad mini has narrowed. The previous generation of full-sized iPad used to weigh about 1.3 lbs. When you compared that to the 0.68 lbs. of the first generation mini, there was a significant reason to choose the smaller device. Today the difference is one lb. for the iPad Air and 0.74 lbs. for the mini. Given that Apple gave the iPad Air a smaller bezel, the difference in width has shrunk from two inches to 1.3.

A small device causes a big problem
The bottom line is, unless the consumer is heavily invested in the iOS ecosystem, the iPad mini is hard to recommend. If you are going to spend $399, you may as well spend $499 and get the extra screen real estate of the iPad Air. Apple did so well making the Air they may have unintentionally made the mini obsolete.

That being said, with most applications being available on either iOS or Android, it's hard to ignore the value that the Google Nexus 7 and Amazon Kindle Fire HDX 7" offer at just $229 each. Given the huge difference in price, it seems likely that Apple will continue losing tablet market share.

Apple had a chance to sell a premium small tablet that customers wanted at a reasonable price. Instead, the company decided to raise the price by more than 20%. With its current price structure, Apple may have alienated the small tablet market. Given the company's growth aspirations, that is a problem that is too big to ignore.

More compelling ideas from The Motley Fool
Our top technology analyst recently infiltrated one of Wall Street's most exclusive gatherings... and left with three incredible investment opportunities, straight from the CEOs. These are profit-building strategies Main Street isn't meant to hear about -- so you must act now before someone shuts us up. Click if you want "industry insider" earnings -- NOW!

The article A Swing and a Miss With the iPad Mini Retina originally appeared on Fool.com.

Chad Henage owns shares of Apple. The Motley Fool recommends Amazon.com, Apple, and Google. The Motley Fool owns shares of Amazon.com, Apple, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Why JinkoSolar Holding, Kirkland's, and Lumos Networks Soared Today

$
0
0

Filed under:

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

Major market benchmarks hit two new key milestones, with the Dow poking above 16,000 and the S&P 500 climbing through the 1,800 mark briefly before falling back toward the end of the day. In the end, the broader stock market dropped slightly, but JinkoSolar Holding , Kirkland's , and Lumos Networks all held on to their double-digit percentage gains on the day. Let's look more closely at these stocks to see why they soared today.

JinkoSolar gained 13%, hitting another multiyear high as the Chinese solar stock announced that its sales rose 11% in the third quarter on a 6% jump in shipment volume. With a huge bottom-line beat as well, JinkoSolar solidified its status as one of the healthier players among China's many solar companies. As the shakeout in Chinese solar continues, JinkoSolar stands to become one of the survivors, putting itself in a strong position to thrive if demand for solar products continues to rise worldwide.


Retailer Kirkland's climbed 15%, adding to its 7% gain on Friday. Several other home-furnishing retailers were down on the day, although as Fool contributor Sean Williams noted earlier today, The Container Store also posted double-digit percentage gains on a relative lack of company-specific news. As the retail industry enters the key holiday season, abrupt moves from smaller players will become more frequent as channel checks reveal early trends in shopping behavior that could add up to huge gains for Kirkland's if they continue.

Lumos Networks climbed 10% as it rebounded following a secondary offering of shares last week. The stock had traded at its current level just two weeks ago before falling after private-equity investor Quadrangle Capital Partners filed to sell about $50 million in Lumos stock last week. The move won't dilute existing shareholders because Lumos isn't offering any stock of its own, but investors apparently concluded that after the market absorbed the sudden hit, Quadrangle's departure won't hurt the company's long-term prospects going forward.

Find next year's winners right now
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!

The article Why JinkoSolar Holding, Kirkland's, and Lumos Networks Soared Today originally appeared on Fool.com.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter: @DanCaplinger. The Motley Fool recommends The Container Store. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Viewing all 9760 articles
Browse latest View live




Latest Images